How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/nyha-class-iii-iv-heart-failure-with-reduced-ejection-fraction.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

NYHA Class III-IV heart failure with reduced ejection fraction — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

NYHA Class III-IV heart failure with reduced ejection fraction (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating NYHA Class III-IV heart failure with reduced ejection fraction, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Aldactone	Spironolactone	Pfizer Inc.	Potassium-sparing diuretic, aldosterone antagonist	Aldosterone receptors at aldosterone-dependent sodium-potassium exchange site in distal convoluted renal tubule

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer Inc. · 1 drug in NYHA Class III-IV heart failure with reduced ejection fraction

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in NYHA Class III-IV heart failure with reduced ejection fraction:

Cite this brief

Drug Landscape (2026). NYHA Class III-IV heart failure with reduced ejection fraction — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/nyha-class-iii-iv-heart-failure-with-reduced-ejection-fraction. Accessed 2026-06-10.

NYHA Class III-IV heart failure with reduced ejection fraction full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing